EcoDrugPlus

Kinase Insert Domain Receptor (A Type Iii Receptor Tyrosine Kinase)

Ensembl ID : ENSIPUG00000010273
Gene Symbol: KDR
3 Cross references
197 Possible Orthologues:

Kinesin Family Member 11

Ensembl ID : ENSIPUG00000014235
Gene Symbol: KIF11
3 Cross references
202 Possible Orthologues:

Kinesin Family Member 5b, B

Ensembl ID : ENSIPUG00000010770
Gene Symbol: KIF5BB
3 Cross references
270 Possible Orthologues:

Lectin, Galactoside Binding Soluble 3a

Ensembl ID : ENSIPUG00000003379
Gene Symbol: LGALS3A
4 Cross references
220 Possible Orthologues:

Leukotriene A4 Hydrolase

Ensembl ID : ENSIPUG00000014626
Gene Symbol: LTA4H
3 Cross references
205 Possible Orthologues:

Leukotriene B4 Receptor

Ensembl ID : ENSIPUG00000014079
Gene Symbol: LTB4R
3 Cross references
142 Possible Orthologues:

Leukotriene B4 Receptor 2a

Ensembl ID : ENSIPUG00000014088
Gene Symbol: LTB4R2A
3 Cross references
157 Possible Orthologues:

Leukotriene B4 Receptor 2b

Ensembl ID : ENSIPUG00000015281
Gene Symbol: LTB4R2B
4 Cross references
167 Possible Orthologues:

Lysine (K)-Specific Demethylase 1a

Ensembl ID : ENSIPUG00000004255
Gene Symbol: KDM1A
3 Cross references
213 Possible Orthologues:

Lysyl Oxidase-Like 2a

Ensembl ID : ENSIPUG00000024508
Gene Symbol: LOXL2A
3 Cross references
210 Possible Orthologues:

Lysyl Oxidase-Like 2b

Ensembl ID : ENSIPUG00000022206
Gene Symbol: LOXL2B
4 Cross references
213 Possible Orthologues:

Macrophage Colony-Stimulating Factor 1 Receptor

Ensembl ID : ENSIPUG00000009288
Gene Symbol: LOC100526732
3 Cross references
10 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).